BRAF and colorectal carcinoma: As recently shown [9], when combined with ABT-263 (structurally related to ABT-737), AZD8055 via the specific suppression of Mcl-1 sensitized CRC cell lines with KRAS or BRAF mutation to undergo apoptosis, a timely result as such CRC entities are refractory to current targeted therapies.